Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
NCT04854434 · Karyopharm Therapeutics Inc · PHASE2 · terminated · last registry update 2023-11-03 · Colorectal cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | Open Targets' class: business administrative | Registry record, Karyopharm Therapeutics Inc |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against XPO1 in colorectal cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision